Company Overview and News

2
Real Estate Sector Awaits Impact From Hurricane Florence

2018-09-15 seekingalpha
On a busy week of economic data and hurricane-related disruptions, US equities advanced 1% while real estate equities finished roughly flat. Housing-related categories await the impact of Hurricane Florence.
HD BAMGF DRE EQIX LEN CG CLGX MDC BAMKF BAM

 
EXL Announces Appointment of Jaynie Studenmund to Board of Directors

2018-09-13 globenewswire
NEW YORK, Sept. 13, 2018 (GLOBE NEWSWIRE) -- EXL (NASDAQ: EXLS), a leading operations management and analytics company, today announced that Jaynie Studenmund, a seasoned executive with significant experience advising and leading digital companies, has been appointed to the Company’s Board of Directors as an independent director effective September 7, 2018. Ms. Studenmund will also be a member of the Audit and Compensation committees of the Board.
EXLS CLGX PNK

 
Australia house prices fall for 11th month as downturn deepens

2018-09-03 theedgemarkets
SYDNEY (Sept 3): Australian housing prices fell for an 11th straight month in August, and further declines are likely as the peak selling season starts.
WBC WBC CLGX WEBNF WBK

 
Hurricane Lane Threatens $8 Billion in Damage to Hawaii

2018-08-23 247wallst
Residents of Hawaii’s Big Island are preparing for the first hurricane-force storm to hit the state since 1992. Hurricane Lane is a category 4 storm that is forecast to make landfall Thursday with winds of up to 145 mph.
CLGX

 
CLGX / CoreLogic, Inc. null

2018-08-20 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,B]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
CLGX

 
'The worst is yet to come': House prices fall by fastest rate in six years

2018-08-01 theage.com.au
House prices have fallen at their fastest rate in more than six years, fuelling concerns that prices in Sydney and Melbourne may fall "too far, too quickly," hurt economic growth and drive anxiety among policymakers.
CLGX

 
'The worst is yet to come': House prices fall by fastest rate in six years

2018-08-01 smh.com.au
House prices have fallen at their fastest rate in more than six years, fuelling concerns that prices in Sydney and Melbourne may fall "too far, too quickly," hurt economic growth and drive anxiety among policymakers.
CLGX

 
Australia House Prices Fall the Most in 7 Years

2018-08-01 theedgemarkets
(Aug 1): Australia’s property slump deepened in July, with housing prices falling the most in almost seven years.
CLGX

 
CoreLogic, INC. 2018 Q2 - Results - Earnings Call Slides

2018-07-26 seekingalpha
The following slide deck was published by CoreLogic, INC. in conjunction with their 2018 Q2 earnings call.
CLGX

 
 
CoreLogic May Home Price Index Jumps More Than 7%

2018-07-03 247wallst
U.S. home prices rose 7.1% in May compared with the same month a year ago, according to data from CoreLogic released Tuesday in the research firm’s Home Price Insights monthly report. The data include sales of distressed properties.
CLGX

6
Australia property prices fall for ninth month on tighter credit

2018-07-02 theedgemarkets
SYDNEY (July 2): Australian housing prices fell for a ninth straight month in June as tighter credit rules weigh on buyers.
CLGX

6
Australia Property Prices Fall for Ninth Month on Tighter Credit - Bloomberg

2018-07-02 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CLGX

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to CLGX / CoreLogic, Inc. on message board site Silicon Investor.

Core Logic Core Logic Core Logic
CUSIP: 21871D103